 SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 GLOBE NEWSWIRE -- Zai Lab Limited NASDAQ: ZLAB; HKEX: 9688, an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List NRDL released by Chinas National Healthcare Security Administration NHSA. ZEJULA niraparib is an oral, once-daily poly ADP-ribose polymerase PARP inhibitor with national Category 1 designation. It has been included in the NRDL as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. 